Does the media favor ESLA or SERA?

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.91 beat Sera Prognostics' score of -0.71 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Which has higher earnings & valuation, PMVP or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.24 N/A

Is PMVP or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% Estrella Immunopharma N/A N/A -328.72%

Does the media refer more to PMVP or ESLA?

In the previous week, PMV Pharmaceuticals had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for PMV Pharmaceuticals and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.91 beat PMV Pharmaceuticals' score of 0.51 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, KLRS or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.24 N/A

Is KLRS or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Estrella Immunopharma N/A N/A -328.72%

Does the media refer more to KLRS or ESLA?

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.91 beat Kalaris Therapeutics' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to YARW or ESLA?

In the previous week, Yarrow Bioscience had 2 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Yarrow Bioscience and 1 mentions for Estrella Immunopharma. Yarrow Bioscience's average media sentiment score of 0.97 beat Estrella Immunopharma's score of 0.91 indicating that Yarrow Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ESLA or CNTB more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -328.72% Connect Biopharma N/A -165.41% -121.58%

Does the media prefer ESLA or CNTB?

In the previous week, Connect Biopharma had 18 more articles in the media than Estrella Immunopharma. MarketBeat recorded 19 mentions for Connect Biopharma and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.91 beat Connect Biopharma's score of 0.24 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Estrella Immunopharma (ESLA) Competitors

$0.47 -0.01 (-1.47%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.47 +0.00 (+0.64%)

As of 10/2/2026 04:04 PM Eastern

Compare

ESLA vs. SERA, PMVP, KLRS, YARW, and CNTB

Should you buy Estrella Immunopharma stock or one of its competitors? Estrella Immunopharma's main competitors and comparable companies include Sera Prognostics (SERA), PMV Pharmaceuticals (PMVP), Kalaris Therapeutics (KLRS), Yarrow Bioscience (YARW), and Connect Biopharma (CNTB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Estrella Immunopharma compare to Sera Prognostics?

Estrella Immunopharma (NASDAQ:ESLA) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Estrella Immunopharma has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Estrella Immunopharma's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Estrella Immunopharma has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Estrella Immunopharma presently has a consensus price target of $8.00, suggesting a potential upside of 1,609.40%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 163.16%. Given Estrella Immunopharma's higher probable upside, equities research analysts plainly believe Estrella Immunopharma is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.91 beat Sera Prognostics' score of -0.71 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Estrella Immunopharma has higher earnings, but lower revenue than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Sera Prognostics	$80K	1,030.63	-$31.93M	-$0.67	N/A

Summary

Estrella Immunopharma and Sera Prognostics tied by winning 7 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Estrella Immunopharma's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
Estrella Immunopharma	N/A	N/A	-328.72%

PMV Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PMV Pharmaceuticals presently has a consensus target price of $4.33, indicating a potential upside of 142.09%. Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,609.40%. Given Estrella Immunopharma's higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, PMV Pharmaceuticals had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for PMV Pharmaceuticals and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.91 beat PMV Pharmaceuticals' score of 0.51 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PMV Pharmaceuticals beats Estrella Immunopharma on 9 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Estrella Immunopharma's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Estrella Immunopharma	N/A	N/A	-328.72%

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.91 beat Kalaris Therapeutics' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Kalaris Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 594.44%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 1,609.40%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kalaris Therapeutics and Estrella Immunopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Estrella Immunopharma compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Yarrow Bioscience had 2 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Yarrow Bioscience and 1 mentions for Estrella Immunopharma. Yarrow Bioscience's average media sentiment score of 0.97 beat Estrella Immunopharma's score of 0.91 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma has lower revenue, but higher earnings than Yarrow Bioscience. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	104.32	-$26.48M	-$14.64	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

Yarrow Bioscience presently has a consensus target price of $58.00, indicating a potential upside of 160.44%. Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,609.40%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Estrella Immunopharma's return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Estrella Immunopharma	N/A	N/A	-328.72%

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Yarrow Bioscience has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Summary

Yarrow Bioscience beats Estrella Immunopharma on 9 of the 15 factors compared between the two stocks.

How does Estrella Immunopharma compare to Connect Biopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Estrella Immunopharma's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Connect Biopharma	N/A	-165.41%	-121.58%

Estrella Immunopharma presently has a consensus price target of $8.00, suggesting a potential upside of 1,609.40%. Connect Biopharma has a consensus price target of $6.14, suggesting a potential upside of 562.66%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Estrella Immunopharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market.

Estrella Immunopharma has higher earnings, but lower revenue than Connect Biopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Connect Biopharma	$60K	972.89	-$55.48M	-$1.19	N/A

In the previous week, Connect Biopharma had 18 more articles in the media than Estrella Immunopharma. MarketBeat recorded 19 mentions for Connect Biopharma and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.91 beat Connect Biopharma's score of 0.24 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Connect Biopharma beats Estrella Immunopharma on 8 of the 14 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESLA vs. The Competition

Export

Metric	Estrella Immunopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.36M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-1.95	13.06	275.67	26.04
Price / Sales	N/A	1,292.17	656.66	110.58
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	-1.73	16.63	10.93	6.31
Net Income	-$13.06M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-2.70%	-2.99%	-2.00%	-1.66%
1 Month Performance	-27.59%	-10.81%	-6.19%	-4.68%
1 Year Performance	-64.27%	19.19%	8.03%	1.57%

Estrella Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESLA Estrella Immunopharma	1.5854 of 5 stars	$0.47 -1.5%	$8.00 +1,609.4%	-64.3%	$20.36M	N/A	N/A	N/A	News Coverage Gap Down
SERA Sera Prognostics	2.3893 of 5 stars	$2.06 -3.3%	$5.50 +167.0%	-35.7%	$84.03M	$80K	N/A	72	Gap Up
PMVP PMV Pharmaceuticals	3.4961 of 5 stars	$1.37 -9.3%	$4.33 +216.3%	+24.3%	$80.72M	N/A	N/A	54
KLRS Kalaris Therapeutics	2.761 of 5 stars	$3.12 -3.7%	$18.75 +501.0%	-59.3%	$77.13M	N/A	N/A	110	News Coverage
YARW Yarrow Bioscience	2.8564 of 5 stars	$27.88 -2.8%	$58.00 +108.0%	N/A	$76.57M	$570K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESLA) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Estrella Immunopharma (ESLA) Competitors

ESLA vs. SERA, PMVP, KLRS, YARW, and CNTB

How does Estrella Immunopharma compare to Sera Prognostics?

Summary

How does Estrella Immunopharma compare to PMV Pharmaceuticals?

Summary

How does Estrella Immunopharma compare to Kalaris Therapeutics?

Summary

How does Estrella Immunopharma compare to Yarrow Bioscience?

Summary

How does Estrella Immunopharma compare to Connect Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Estrella Immunopharma (ESLA) Competitors

ESLA vs. SERA, PMVP, KLRS, YARW, and CNTB

How does Estrella Immunopharma compare to Sera Prognostics?

Is ESLA or SERA more profitable?

Which has more volatility and risk, ESLA or SERA?

Do analysts prefer ESLA or SERA?

Does the media favor ESLA or SERA?

Do institutionals & insiders have more ownership in ESLA or SERA?

Which has preferable valuation and earnings, ESLA or SERA?

Summary

How does Estrella Immunopharma compare to PMV Pharmaceuticals?

Is PMVP or ESLA more profitable?

Which has more volatility & risk, PMVP or ESLA?

Which has higher earnings & valuation, PMVP or ESLA?

Do institutionals and insiders believe in PMVP or ESLA?

Do analysts prefer PMVP or ESLA?

Does the media refer more to PMVP or ESLA?

Summary

How does Estrella Immunopharma compare to Kalaris Therapeutics?

Is KLRS or ESLA more profitable?

Which has preferable valuation & earnings, KLRS or ESLA?

Do insiders & institutionals have more ownership in KLRS or ESLA?

Does the media refer more to KLRS or ESLA?

Which has more volatility & risk, KLRS or ESLA?

Do analysts recommend KLRS or ESLA?

Summary

How does Estrella Immunopharma compare to Yarrow Bioscience?

Does the media refer more to YARW or ESLA?

Which has higher earnings & valuation, YARW or ESLA?

Do analysts rate YARW or ESLA?

Is YARW or ESLA more profitable?

Do institutionals & insiders believe in YARW or ESLA?

Which has more risk and volatility, YARW or ESLA?

Summary

How does Estrella Immunopharma compare to Connect Biopharma?

Is ESLA or CNTB more profitable?

Do analysts prefer ESLA or CNTB?

Which has more volatility and risk, ESLA or CNTB?

Which has better valuation and earnings, ESLA or CNTB?

Does the media prefer ESLA or CNTB?

Do institutionals & insiders hold more shares of ESLA or CNTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools